Chris A. Gentry

Chris A. Gentry

Auto-generated profile, based on publicly available information

Chris A. Gentry

Pharmacy Service, Oklahoma City Veterans Affairs Health Care System, Oklahoma City, OK, USA

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2018 in Clinical Microbiology and Infection
Verified
Journal Article
Closed access
SGS.E. Giancola
S.E. Giancola
RWR.J. Williams
R.J. Williams
CGC.A. Gentry
C.A. Gentry

1 January 2009 in Critical Care Medicine
Verified
Journal Article
Closed access
CGChris A. Gentry
Chris A. Gentry
KGKristin Busse Gross
Kristin Busse Gross
BSBhanu Sud
Bhanu Sud
DDDouglas A. Drevets
Douglas A. Drevets
Key clinical trials involving drotrecogin alfa (activated) (or recombinant human activated protein C) excluded patients with specific baseline bleeding precautions. However, not all such precautions are considered contraindications to treatment with recombinant human activated protein C in current product labeling. To compare outcomes of patients receiving recombinant human activated protein C with or without baseline bleeding precautions as defined by the Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) trial. Retrospective medical record review. Two tertiary care institutions: An academic medical center and an affiliated Veterans Affairs Medical Center. All patients receiving recombinant human activated protein C for treatment of sepsis. Demographic information, characteristics associated with inclusion and exclusion criteria of the PROWESS trial, and 30-day postdischarge outcomes. Seventy-three patients received recombinant human activated protein C. Serious bleeding events occurred in 7 of 20 patients (35%) with any baseline bleeding precaution vs. only 2 of 53 patients (3.8%) without any bleeding precautions (p < 0.0001). More patients with a baseline bleeding precaution died compared with patients without any bleeding precautions (65% vs. 24.5%, p = 0.0015). Patients with a baseline bleeding precaution had a higher mean Acute Physiology and Chronic Health Evaluation II score (27.5 vs. 22.7, p = 0.015). Multivariate analysis demonstrated that the presence of a baseline bleeding precaution was the only independent variable associated with occurrence of serious bleeding events. The presence of a baseline bleeding precaution, increased Acute Physiology and Chronic Health Evaluation II score, and the presence of bloodstream infection were independent variables associated with mortality. Patients with severe sepsis who received recombinant human activated protein C with baseline bleeding precautions as defined by product labeling had significantly higher rates of both serious bleeding events and deaths compared with those without bleeding precautions. These data suggest that strict adherence to PROWESS trial exclusion criteria would further limit serious bleeding events associated with the use of recombinant human activated protein C.

1 September 2010 in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
Verified
Journal Article
Closed access
PDF file
QMQuentin Minson
Quentin Minson
CGChris A. Gentry
Chris A. Gentry

1 August 2019 in Clinical Microbiology and Infection
Verified
Journal Article
Closed access
CGC.A. Gentry
C.A. Gentry
PNP.K. Nguyen
P.K. Nguyen
STS. Thind
S. Thind
GKG. Kurdgelashvili
G. Kurdgelashvili
GSG.H. Skrepnek
G.H. Skrepnek
RWR.J. Williams
R.J. Williams

23 January 2023 in Journal of Infection
Verified
Journal Article
Closed access
CGChris A. Gentry
Chris A. Gentry
PNPhoi Nguyen
Phoi Nguyen
STSharanjeet K Thind
Sharanjeet K Thind
GKGeorge Kurdgelashvili
George Kurdgelashvili
RWRiley J. Williams
Riley J. Williams

16 January 2013 in Annals of Pharmacotherapy
Verified
Journal Article
Closed access
JCJenny I Chen
Jenny I Chen
LSLeonard N Slater
Leonard N Slater
GKGeorge Kurdgelashvili
George Kurdgelashvili
KHKhawaja O Husain
Khawaja O Husain
CGChris A Gentry
Chris A Gentry
BACKGROUND: The introduction of the health care–associated pneumonia (HCAP) categorization expanded recommendations for broad-spectrum empiric antibiotics to pneumonia patients presenting from the community with recent health care–system exposure. However, the efficacy of such regimens in improving clinical outcomes in these patients has not been well established. OBJECTIVE: To compare the clinical outcomes of HCAP patients treated initially with HCAP guideline–concordant antibiotic regimens to those treated initially with community-acquired pneumonia (CAP) guideline-concordant antibiotic regimens. METHODS: This retrospective study included HCAP patients presenting from home and admitted to general medical wards. HCAP regimen patients were treated empirically with at least 1 antipseudomonal agent. All other patients were assigned to the CAP regimen group. The primary end point was clinical cure at 30 days postdischarge. Subgroup analysis was performed in patients hospitalized 1–30 days and 31–90 days before the HCAP admission. RESULTS: Of 228 HCAP admissions, 122 patients received CAP regimens and 106 received HCAP regimens. The 2 groups were similar at baseline, including Pneumonia Severity Index scores. Attributable clinical cure occurred in 75.4% of CAP regimen patients and 69.8% of HCAP regimen patients (p = 0.34). Overall clinical cure occurred in 59.8% of CAP regimen patients and 54.7% of HCAP regimen patients (p = 0.44). The CAP regimen group used fewer days of intravenous antibiotics (4.39 vs 7.75, p < 0.0001) and had shorter lengths of stay (6.36 vs 8.58 days, p < 0.0001). For patients hospitalized 31–90 days earlier, clinical cure was higher in the CAP regimen group (attributable, 82.9% vs 60.0%, p = 0.0090; overall, 67.1% vs 47.5%, p = 0.044). CONCLUSIONS: Compared to CAP guideline–concordant regimens, treatment of HCAP with HCAP guideline–concordant regimens did not increase clinical cure rates and was associated with lower clinical cure rates in patients hospitalized 31–90 days prior to the HCAP admission. This study suggests that broad-spectrum empiric antibiotics may not be necessary in all HCAP patient groups.